Addictions Research Programs
The Department of Psychiatry is involved in a range of research projects and clinical initiatives that seek to understand, support and treat patients who are struggling with substance use disorders, which are so often comorbid with other psychiatric conditions. Researchers in the department are working to better understand the needs and characteristics of patients with substance use disorders from both qualitatively and quantitatively.
Through our presence in the Emergency Department, inpatient addiction consult services, and our robust outpatient addiction treatment, the Psychiatry Department is deeply involved in BMC’s effort to fight the addiction crisis. Additionally, in March 2017, BMC launched the Grayken Center for Addiction, made possible by a $25 million grant from the Grayken family. The creation of this center recognizes BMC as a leader in the field of addiction treatment. The Department seeks to align our work with the Grayken Center and to strengthen our commitment to improving the lives of people affected by substance use disorders.
|Michael Dawes, MD, is Vice-Chair for Addiction Psychiatry. Dr. Dawes is a graduate of University of North Carolina School of Medicine and has Board certifications in both Addiction Psychiatry and Addiction Medicine. He has been recipient of a Mentored Clinical Scientist Development Award from National Institute on Drug Abuse (NIDA) examining developmental trajectories of children of substance-use disordered parents who are at high-risk for developing substance use disorders. Dr. Dawes has have been Principal Investigator and Co-Investigator on clinical and prospective cohort studies funded by National Institutes of Health (NIH), examining relationships among impulsivity, substance use disorders, and suicidal behavior in adolescents and adults. He has conducted clinical trials in SUD adolescents and adults. His implementation science foci include improved access to medications that treat Substance Use Disorders, and enhancing engagement in SUD treatment, especially for racial and ethnic minorities. He has experience in mentoring residents and fellows to pursue careers in Addiction Treatment. Dr. Dawes has keen interest in fostering development of the next generation of clinician-researchers who treat addiction and co-occurring mental health disorders.|
|Dr. Renner is Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry for the VA Boston Healthcare System. He graduated from Yale University and Case University School of Medicine. Since 1979 he has been working at the Boston VA where he currently directs their outpatient addiction treatment program. In addition, he is Associate Director of the Boston University Medical Center General Psychiatry Residency Program and Director of their Addiction Psychiatry Residency. Dr. Renner has written and lectured extensively on the treatment of alcoholism and drug addiction. He is the immediate past-President of the American Academy of Addiction Psychiatry, and Vice-Chair of the American Psychiatric Association Council on Addiction Psychiatry. In 2010, Dr. Renner co-edited the Handbook of Office-Based Buprenorphine Treatment for the American Psychiatric Press, Inc. He is a member of the Data Safety Monitoring Board for the Clinical Trials Network of the National Institute on Drug Abuse, a member of the Clinical Advisory Committee of the Physician Health Service of the Massachusetts Medical Society, a Consultant to the Department of Psychiatry, Massachusetts General Hospital, and a member of the faculty of the Harvard Medical School Division on Addictions. He is also former medical director of the SAMHSA funded Physicians Clinical Support System-Buprenorphine.|
|Dr. Augello is an Addiction Psychiatrist with a special expertise and interest in women’s health and in particular the treatment of pregnant women with co-occurring psychiatric and substance abuse conditions. She provides services in our Outpatient Behavioral Health Clinic as well as an embedded provider in the OBAT and OBGYN clinics. Dr Augello received her M.D. from State University of New York Downstate in Brooklyn, NY (2011). Her Fellowship in Addiction Psychiatry was completed at the University of Washington in Seattle, WA, and she served as Resident in Psychiatry at the University of Washington in Seattle, WA (2013), and a Resident in Obstetrics and Gynecology at Mount Sinai Hospital in New York, NY (2011).|
|Dr. Huiping Zhang’s research laboratory conducts research on the genetic, epigenetic and pharmacogenetics of substance dependence and related disorders. He utilizes a number of approaches to better understand the effect of gene variants and DNA methylation changes that may influence an individual’s predisposition for substance dependence, with the ultimate goal of identifying innovative approaches for the prevention and treatment of substance dependence and comorbid disorders. For more information about Dr. Zhang’s work, please visit his BUSM profile.|
|Dr. Eric Devine has been involved in addictions research at Boston Medical Center since 1999, with an emphasis in alcohol and cocaine addictions. He has extensive experience in manualized treatments for addiction and has co-authored several treatment manuals developed for use in clinical trials for a range of funding agencies (e.g., NIHM, NIDA, SAMHSA). For more information about Dr. Devine’s research, please visit the Clinical Studies Unit webpage. For more information about Dr Devine’s work, please visit his BUSM profile.|
|In addition to providing clinical care for patients with addiction disorders, Dr. Tae Woo Park is leveraging qualitative research methods to investigate both patient and provider perspectives on the use of benzodiazepines in patients receiving treatment opioid addiction. For more information about Dr. Park’s work, visit his BUSM profile.
|Dr. Cristina Montalvo, an Consult-Liaison Psychiatry Fellow at BMC, has been conducting a large-scale medical record chart review study of BMC patients diagnosed with opiate use disorder and treated with buprenorphine, a common medication used in the treatment of opiate use disorder, at all BMC outpatient clinics, including mental health outpatient services, to examine clinical and demographic factors which may be correlated with overall outcomes in patients with opiate use disorders engaged in opioid agonist treatment.|